Liquid Biopsy Market 2025 - 2033: Used in Circulating Tumor Cells Detection, Methylation Biomarker Detection

The global liquid biopsy market is experiencing significant growth, driven by the rising prevalence of cancer, increasing demand for personalized medicine, and advancements in non-invasive diagnostic technologies. In 2024, the market reached a value of USD 2.3 billion and is projected to expand to USD 7.2 billion by 2033, exhibiting a robust CAGR of 12.82% during 2025-2033. Liquid biopsies offer a less invasive alternative to traditional tissue biopsies, enabling early detection and monitoring of cancer through the analysis of circulating biomarkers in bodily fluids. This approach enhances patient comfort and facilitates timely therapeutic interventions, contributing to improved clinical outcomes.

Request for a sample copy of this report:
https://www.imarcgroup.com/liquid-biopsy-market/requestsample

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Years: 2025-2033

Liquid Biopsy Market Key Takeaways

• Market Size & Growth: The global liquid biopsy market was valued at USD 2.3 billion in 2024 and is anticipated to reach USD 7.2 billion by 2033, growing at a CAGR of 12.82% during the forecast period.
• Dominant Product Segment: Kits and reagents represent the largest product segment, driven by their critical role in facilitating liquid biopsy procedures.
• Leading Biomarker: Circulating tumor cells (CTCs) hold the largest share among circulating biomarkers, owing to their utility in cancer detection and monitoring.
• Prevalent Cancer Type: Lung cancer accounts for most of the market share, reflecting the high incidence and the effectiveness of liquid biopsy in its management.
• Primary End Users: Hospitals and laboratories are the predominant end users, utilizing liquid biopsy for diagnostic and monitoring purposes.
• Regional Leadership: North America leads the market, attributed to advanced healthcare infrastructure and high adoption of innovative diagnostic technologies.
• Technological Advancements: Continuous innovations in sequencing technologies and bioinformatics are enhancing the accuracy and applicability of liquid biopsies.

Market Growth Factors

1 - Technological Advancements Enhancing Liquid Biopsy Precision

Innovations in technology are making a big difference in the precision and effectiveness of liquid biopsy techniques. With recent breakthroughs in next-generation sequencing (NGS), digital PCR, and microfluidics, we're seeing a notable improvement in the accuracy of cancer biomarker detection. These advanced tools facilitate comprehensive genomic profiling, which helps us identify genetic mutations and tailor treatment strategies to individual patients. Additionally, the use of bioinformatics allows for thorough data analysis and interpretation, leading to more accurate cancer diagnoses and real-time monitoring of diseases. As these technologies progress, they widen the range of clinical applications, solidifying liquid biopsy's role as a vital element in today's oncology diagnostics.

2 - Expanding Clinical Significance and Adoption of Liquid Biopsy

Technology is advancing at lightning speed, and it's making a huge difference in the performance and accuracy of liquid biopsy techniques. With breakthroughs in next-generation sequencing (NGS), digital PCR, and microfluidics, we're now able to detect cancer biomarkers with much greater precision. This means we can conduct detailed genomic profiling and choose targeted therapies more effectively. Plus, when we pair these innovations with powerful bioinformatics tools, we can analyze data comprehensively for accurate diagnoses and ongoing monitoring. As we keep pushing forward, liquid biopsy is proving to be an essential tool in today's oncology diagnostics, broadening its clinical significance and acceptance.

3 - Personalized Medicine Fuels Growth of Liquid Biopsy Market

The rising trend towards personalized medicine is boosting the liquid biopsy market. Patients and healthcare providers are now on the lookout for diagnostic tools that can offer real-time, customized insights into disease progression and how well treatments are working. Liquid biopsy is stepping up to meet this demand by allowing for continuous monitoring of tumor genetics, which helps tailor therapies to each patient's specific molecular profile. This not only enhances the precision of treatments but also reduces side effects and promotes proactive care. Moreover, it's vital for identifying minimal residual disease and early relapses, providing valuable information for long-term disease management. As personalized healthcare continues to grow, liquid biopsy is establishing itself as a fundamental aspect of precision oncology.

Market Segmentation

Breakup by Product and Service

• Kits and Reagents: Essential for the preparation and analysis of samples in liquid biopsy procedures, facilitating the detection of specific biomarkers.
• Platforms and Instruments: Comprise the technological infrastructure required for conducting liquid biopsy tests, including sequencing and imaging systems.
• Services: Encompass diagnostic and analytical services provided by specialized laboratories utilizing liquid biopsy techniques.

Breakup by Circulating Biomarker

• Circulating Tumor Cells (CTCs): Cancer cells that have shed into the bloodstream from a primary tumor, serving as indicators for metastasis and disease progression.
• Extracellular Vesicles: Membrane-bound particles released by cells, containing proteins and nucleic acids, useful for intercellular communication and as disease biomarkers.
• Circulating Tumor DNA (ctDNA): Fragments of DNA released into the bloodstream by tumor cells, providing genetic information about the cancer.
• Others: Includes additional biomarkers such as microRNAs and exosomes, contributing to the comprehensive analysis of cancer.

Breakup by Cancer Type

• Lung Cancer: Accounts for the majority of the market share, with liquid biopsy aiding in early detection and monitoring of treatment efficacy.
• Breast Cancer: Utilizes liquid biopsy for detecting specific mutations and assessing response to targeted therapies.
• Colorectal Cancer: Employs liquid biopsy for screening and monitoring minimal residual disease post-treatment.
• Prostate Cancer: Benefits from non-invasive testing to detect genetic alterations and guide therapeutic decisions.
• Liver Cancer: Liquid biopsy assists in early diagnosis and tracking disease progression in hepatocellular carcinoma.
• Others: Encompasses various other cancer types where liquid biopsy is being explored for diagnostic and monitoring purposes.

Breakup by End User

• Hospitals and Laboratories: Primary users of liquid biopsy tests for diagnostic and monitoring purposes in clinical settings.
• Academic and Research Centers: Engage in the development and validation of liquid biopsy technologies and applications.
• Others: Includes specialized clinics and diagnostic centers utilizing liquid biopsy for patient management.

Breakup by Region

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Regional Insights

North America is the leader in the liquid biopsy market due to its sophisticated healthcare infrastructure, rapid adoption of novel diagnostic technologies, and heavy research and development investments. The region's emphasis on early cancer detection and personalized medicine also drives demand for liquid biopsy solutions. Additionally, favorable regulatory environments and reimbursement policies ease the adoption of these technologies in clinical settings.

Recent Developments & News

Recent developments in the liquid biopsy industry underscore its growing contribution to cancer diagnosis and management. In May 2024, VESICA HEALTH, INC. introduced the AssureMDx test, which improves early bladder cancer detection. In April 2024, SOPHiA GENETICS agreed with Nigeria-based Syndicate Bio to implement MSK-ACCESS powered by SOPHiA DDM with the aim of enhancing genomic profiling capabilities. In addition, City of Hope partnered with DELFI Diagnostics to introduce the FirstLook Lung test, a blood test that is intended to enhance lung cancer detection rates among underserved populations. These advancements highlight the increasing focus on non-invasive, precise, and affordable cancer diagnostics.

Key Players

• ANGLE plc
• Biocept Inc.
• Bio-Rad Laboratories Inc
• Epigenomics AG
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Guardant Health Inc.
• Illumina Inc.
• MDxHealth SA
• Menarini Silicon Biosystems
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

Ask Analyst for Customization:
https://www.imarcgroup.com/request?type=report&id=5125&flag=C

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.